Objective-Adiponectin is an adipocyte-derived, secreted protein that is implicated in protection against a cluster of related metabolic disorders. Mice lacking adiponectin display impaired hepatic insulin sensitivity and respond only partially to peroxisome proliferator-activated receptor ␥ agonists. Adiponectin has been associated with antiinflammatory and antiatherogenic properties; however, the direct involvement of adiponectin on the atherogenic process has not been studied. Methods and Results-We crossed adiponectin knockout mice (Adn Ϫ/Ϫ ) or mice with chronically elevated adiponectin levels (Adn Tg ) into the low-density lipoprotein receptor-null (Ldlr Ϫ/Ϫ ) and the apoliprotein E-null (Apoe Ϫ/Ϫ ) mouse models. Adiponectin levels did not correlate with a suppression of the atherogenic process. Plaque volume in the aortic root, cholesterol accumulation in the aorta, and plaque morphology under various dietary conditions were not affected by circulating adiponectin levels. In light of the strong associations reported for adiponectin with cardiovascular disease in humans, the lack of a phenotype in gain-and loss-of-function studies in mice suggests a lack of causation for adiponectin in inhibiting the buildup of atherosclerotic lesions. Conclusion-These data indicate that the actions of adiponectin on the cardiovascular system are complex and multifaceted, with a minimal direct impact on atherosclerotic plaque formation in preclinical rodent models. (Arterioscler Thromb Vasc Biol. 2010;30:1159-1165.)
T he increasing prevalence of obesity and its association with the pathogenesis of cardiovascular disease has evoked great interest in understanding the impact of adipokines on vascular integrity, systemic inflammation, and atherosclerosis. 1 Adipokines are factors secreted from adipose tissue that play a key role in systemic energy homeostasis. Many of them, including leptin, resistin, and retinol binding protein-4, are dysregulated in obesity. 2 Similarly, proinflammatory cytokines tend to be upregulated in the obese state as well. 3 Adiponectin is a secreted adipokine abundantly expressed in differentiated adipocytes. 4 Adiponectin levels correlate negatively with body mass index and enhanced inflammation within the adipose tissue. 5 In humans, adiponectin levels correlate inversely with risk factors for cardiovascular disease, including visceral adiposity, hyperlipidemia, and high-density lipoprotein (HDL) cholesterol levels, underscoring a potential value of adiponectin as a biomarker. 6 Hotta et al demonstrated that adiponectin levels of diabetics with coronary artery disease are lower than those of diabetics without coronary artery disease or of nondiabetics. 7 In contrast, high adiponectin levels were associated with a reduced risk for myocardial infarction. 8 A number of additional epidemiological studies suggest a link between adiponectin and the pathologies of cardiovascular disease, although no conclusions were drawn about whether this relationship is correlative or causal.
Adiponectin may have antiatherogenic and antiinflammatory effects. 9 Although adiponectin is frequently measured as a marker for cardiovascular disease in the clinical area, to date, only limited systematic studies have been published that address the direct effects of adiponectin on atherosclerosis in preclinical models. We therefore embarked on a comprehen-sive analysis of commonly used atherosclerosis mouse models that were made adiponectin deficient or that have mildly elevated levels of adiponectin by means of overexpression of an adiponectin transgene. 10, 11 We exposed these mice to various diets to differentiate between correlative and causal effects of adiponectin. For example, we fed the mice a nonobesogenic diet intended to prevent excess adiposity or insulin resistance, yet causing significant hypercholesterolemia. Alternatively, we generated diet-induced obesity using a high-fat "Western style" diet. Interestingly, independently of the genetic or dietary modality we applied, we were unable to detect changes of atherosclerosis associated with adiponectin levels. Our observations may suggest a lack of direct causation for adiponectin in protecting against the infiltration of macrophages, cholesterol deposition, and necrosis within the atherosclerotic lesions.
Our studies also addressed the effects of peroxisome proliferator-activated receptor ␥ (PPAR␥). Pharmacological activation of this nuclear receptor with a small molecule agonist is the single most potent means by which to induce adiponectin secretion. 12 PPAR␥ activation improves insulin sensitivity and various cardiovascular risk factors. However, prolonged treatment with selective PPAR␥ agonists from the thiazolidinedione class is associated with increased adiposity and edema, and substantial concern has been raised regarding the safety of these drugs. 13, 14 Pro-and antiatherogenic roles have been attributed to PPAR␥ activation. In fact, Thorp et al recently demonstrated that pioglitazone exposure can increase macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions. 15 In this study, we analyzed adiponectin-dependent and -independent effects of chronic PPAR␥ agonism on atherosclerosis in mice. We examined lesion size in adiponectin and low-density lipoprotein (LDL) receptor-deficient models on long-term PPAR␥ agonist treatment. In our experimental paradigm, PPAR␥ activation did not reveal beneficial effects on atherosclerosis. In fact, we found a small but significant increase in the average area of lesions specifically within the brachiocephalic branch of the aorta, related to the agonist treatment.
Methods
Detailed information about the materials and methods used can be found in the supplemental data, available online at http://atvb.ahajournals.org.
Animals and Diets
Animals were maintained in a pathogen-free facility, and all experimental protocols were approved by the institutes for animal studies of the Albert Einstein College of Medicine and the University of Texas Southwestern Medical Center. Mice were group housed and were on an alternating 12-hour light and dark cycle under controlled environmental conditions (22°C to 25°C, 40% to 50% humidity) with free access to food and water. Adiponectin knockout mice were generated as described previously 10 and backcrossed for at least 6 generations onto a C57BL/6J background in all studies, with exception of the first study, for which the mice were backcrossed 5 times.
Adiponectin transgenic mice (Adn Tg ) were generated as described by Combs et al. 11 
Results

Adiponectin Deficiency Does Not Accelerate the Formation of Atherosclerotic Lesions in Lean, LDL Receptor-Deficient Mice
The majority of our studies were performed using the LDL receptor knockout model (Ldlr Ϫ/Ϫ ). 16, 17 Adiponectin knockout mice (Adn Ϫ/Ϫ ) 10 were crossed with Ldlr Ϫ/Ϫ mice to generate double knockout mice (Ldlr/Adn Ϫ/Ϫ ). Male mice were fed a low-fat diet (10% kcal from fat) containing 0.15% cholesterol, a regimen that causes substantial atherosclerotic lesions within 3 to 4 months but does not evoke metabolic complications such as obesity and insulin resistance. 18 Total cholesterol levels were elevated to approximately 800 mg/dL in all groups, whereas adiponectin levels were not affected by the dietary intervention (Supplemental Table I ). After 3 months on the diet, mice were lean and had normal glucose levels. The lack of adiponectin per se had no effect on total plasma lipids and lipoprotein distribution, as seen in Adn Ϫ/Ϫ mice in the absence of the Ldlr Ϫ/Ϫ mutation (Supplemental Figure I) .
To assess the influence of adiponectin on the vasculature, we determined atherosclerosis at the aortic root and in the brachiocephalic artery (BCA). Macroscopic lesions were observed underneath most of the valve leaflets and near the aortic branches but were generally absent from the thoracic or abdominal aorta. As shown in Figure 1 , the lesion area within the aortic root ( Figure 1A ) and the BCA ( Figure 1B ) was not affected by adiponectin (no drug; Ldlr Ϫ/Ϫ versus Ldlr/Adn Ϫ/Ϫ ), suggesting that adiponectin does not affect the atherogenic process. To exclude the possibility of a phenomenon unique to the Ldlr Ϫ/Ϫ model, we generated apolipoprotein E-deficient, adiponectin-deficient double knockout mice (Apoe Ϫ/Ϫ / Adn Ϫ/Ϫ ). Total cholesterol was 116Ϯ17 mg/dL in wild-type versus 143Ϯ17 in Adn Ϫ/Ϫ mice when fed a high-fat, highcholesterol diet. Deletion of Apoe Ϫ/Ϫ dramatically increased plasma cholesterol levels (841Ϯ27 mg/dL in wild-type versus 808Ϯ60 in Adn Ϫ/Ϫ ), independently of adiponectin levels. More importantly, as in the Ldlr Ϫ/Ϫ model, adiponectin deficiency had no effect on atherosclerosis in Apoe Ϫ/Ϫ mice (Supplemental Figure II ).
Pharmacological Induction of Adiponectin by PPAR␥ Agonism Does Not Prevent Atherosclerosis in Lean Mice
PPAR␥ agonists have been evaluated in various long-term human studies for potential cardiovascular benefits, with mixed results. 19, 20 PPAR␥ activation causes an increase in plasma adiponectin levels, particularly the high molecular weight form. 12 Selective PPAR␥ ligands of the thiazolidinedione class (troglitazone and rosiglitazone) have been shown to inhibit atherosclerosis in Ldlr Ϫ/Ϫ mice. 21, 22 To assess whether these effects may be secondary to an upregulation of adiponectin, we included 2 parallel groups that received a PPAR␥-selective, nonthiazolidinedione agonist (COOH) at 30 mg/kg body weight per day in feed. As expected, COOH treatment increased plasma adiponectin levels in male mice approximately 4-fold over basal (Supplemental Table I ). COOH has been shown previously to elicit a robust signature of hepatic PPAR␥-responsive genes virtually identical to the profile obtained with rosiglitazone on gene expression analysis on microarrays. 23, 24 Lesion area was similar within the aortic root of Ldlr Ϫ/Ϫ and Ldlr/Adn Ϫ/Ϫ mice treated with COOH ( Figure 1A ). Interestingly, we found a small but significant increase in average area of lesions within the BCA related to COOH treatment (Ldlr Ϫ/Ϫ ; no drug versus COOH; Figure 1B ). This effect was absent in Adn Ϫ/Ϫ mice (COOH, Ldlr Ϫ/Ϫ versus Ldlr/Adn Ϫ/Ϫ ; Figure 1B ), suggesting that this increase is dependent on the elevation of plasma adiponectin induced by PPAR␥. Lesions within the BCA tend to be more advanced than lesions in other areas, and analysis of this region has been used mainly for qualitative purposes. 25 Further investigation of the role of COOH treatment on the quality and quantity of lesions within the BCA was beyond the scope of this investigation and will be presented elsewhere. Lack of adiponectin per se did not affect atherosclerotic lesion area or distribution. It is important to note that under these conditions (ie, nonobesogenic, low-fat diet), COOH treatment had no effect on overall plasma glucose levels or body weight. All groups gained similar amounts of body weight (average weight gain, 9.9Ϯ1.3 g) over the course of the study. COOH treatment did not affect total or HDL cholesterol levels, whereas triglycerides were slightly elevated at the end of the study (COOH; Supplemental Table I ).
Adiponectin Deficiency Does Not Promote Atherosclerosis Secondary to Metabolic Disturbances in Mice
On the basis of our initial studies, we concluded that the manifestation of several aspects of the metabolic syndrome (ie, insulin resistance, increased adiposity and dyslipidemia) may be necessary to unravel a putative role of adiponectin in the atherogenic process. This assumption is in line with the fact that genetic ablation of adiponectin causes a mild metabolic phenotype unless challenged with a high-fat diet. We hypothesized that adiponectin may act indirectly through its overall effects on metabolic and inflammatory parameters. To address this question, we exposed Ldlr/Adn Ϫ/Ϫ mice to a high-caloric Western-type diet (WD; 42% kcal from fat, 42% kcal from carbohydrates, and 0.2% cholesterol). We included females because plasma adiponectin levels are higher in females than in males, and one can assume that the extent of lesion formation may be gender related. After 4 months on WD, all groups were obese and hyperglycemic ( Supplemental Table II ). Both genders developed severe hypercholesterolemia and hypertriglyceridemia independent of their respective adiponectin levels. Lipoprotein profiles were indistinguishable between Ldlr/Adn Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice (data not shown). Adiponectin levels tended to be lower at the end of the study, consistent with an adiposity-associated suppression of adiponectin secretion ( Supplemental Table II ). 26 Atherosclerosis was assessed as cholesterol and cholesterol ester content in the aortic wall. This lipid extraction method has been validated and correlates well with the assessment of atherosclerotic lesions by en face lipid staining or intima/ media thickness. 27 The measurement considers surface area as well as volume and distribution of lesions, including cholesterol depositions that may be undetectable by visual methods. At the end of the study, all mice had increased body weight, hyperlipidemia, and elevated basal glucose levels, and there was no difference in the deposition of cholesterol in aortas of female and male Ldlr/Adn Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice (Figure 2A and 2B) .
In a separate cohort, we assessed lesion area by morphological methods. We analyzed cross-sectional and necrotic lesion area in the aortic roots of both female and male mice ( Figure 2C and 2D). Note that plaque necrosis is associated with vulnerable plaques and culprit lesions in humans. 28 None of the measurements revealed a correlation between the adiponectin genotype and morphology of the plaques. We concluded that (1) adiponectin does not directly suppress early stages of the atherogenic process, (2) a role of adiponectin may be masked by compensatory mechanisms that could have evolved as a consequence of a germ line deletion of adiponectin, 29, 30 or (3) adiponectin may affect later stages of the atherosclerotic process, such as plaque rupture or lumenal thrombosis, which are not a component of these murine models. 25 
Elevated Adiponectin Levels Do Not Prevent Atherosclerosis
We have shown previously that adiponectin overexpression leads to a significant improvement of dyslipidemia in mice. 5 The transgenic expression of an adiponectin deletion mutant (Adn Tg ) causes a moderate increase of steady state adiponectin concentrations in the circulation by approximately 2-to 3-fold over baseline, similar to levels achieved by activation of PPAR␥. 5, 11 Adiponectin overexpression increases lipid clearance and lipoprotein lipase activity and improves the suppression of endogenous glucose production in the liver. We crossed Adn Tg mice into the Ldlr Ϫ/Ϫ background (Ldlr/ Adn Tg ) and determined atherosclerosis on a WD. Body weight, adiponectin, glucose levels, triglyceride, and total and HDL cholesterol after 3 months on the diet are shown in Supplemental Table III . On average, males gained 16.5Ϯ0.9 g and females 11.4Ϯ0.8 g independently of the genotype. Adiponectin levels were 3-to 3.5-fold higher in Ldlr/Adn Tg mice than in Ldlr Ϫ/Ϫ mice and slightly elevated in females but not in males at the end of the study. Fasting glucose was significantly lower in Ldlr/Adn Tg mice than in Ldlr Ϫ/Ϫ mice throughout the study ( Supplemental Table III ) and correlated with an improved response to an oral glucose challenge in both genders at the end of the study (females; Figure 3A , males; Figure 3B ). Ldlr Ϫ/Ϫ mice were mildly glucose intolerant, and this defect was significantly improved in Ldlr/ Adn Tg mice. Before feeding of the WD, total cholesterol and triglyceride levels were significantly lower in Ldlr/Adn Tg compared with Ldlr Ϫ/Ϫ mice, whereas HDL cholesterol was independent of the genotype ( Supplemental Table III ; beginning of study: males, nϭ11 to 12; females, nϭ15 to 17). After 4 months on the WD, total cholesterol and triglyceride levels were dramatically increased in all groups independent of the genotype ( Supplemental Table III ; end of study). In males, HDL cholesterol was significantly increased in Ldlr/Adn Tg mice compared with Ldlr Ϫ/Ϫ mice, and a similar trend was observed in female mice.
Lipoprotein distribution and atherosclerosis were measured in a separate cohort of mice after 4 months on WD. In this study, we measured a trend in male mice and a significant reduction of total cholesterol in female Ldlr/Adn Tg mice compared with Ldlr Ϫ/Ϫ mice ( Figure 4A ). Triglycerides were reduced significantly in both female and male Ldlr/Adn Tg mice ( Figure 4B ). This reduction in total lipid levels was not seen in plasma samples collected from tail blood in the previous study (Supplemental Table III ). The discrepancy may be explained by variations in sample preparation or among cohorts. The lipoprotein profile measured by size exclusion chromatography revealed reduced cholesterol levels in very-low-density lipoprotein and intermediate-density/low-density lipoprotein fractions from both female and male Ldlr/Adn Tg mice compared with Ldlr Ϫ/Ϫ mice, whereas HDL fractions were unaffected ( Figure 4C and 4E, females and males, respectively). Lower triglycerides were observed in female and male Ldlr/Adn Tg mice and were mostly accounted for by very-low-density lipoprotein fractions ( Figure 4D and 4F, females and males, respectively).
As before, atherosclerosis was quantified by the lipid extraction method. Despite an improved lipoprotein profile, we could not detect differences in cholesterol deposited in the aortic wall between Ldlr/Adn Tg and Ldlr Ϫ/Ϫ (females; Figure  5A , males; Figure 5B ). These results were confirmed by a histological assessment of lesions within the aortic root (nϭ9) after staining with oil red O ( Figure 5C ). Lesion area was independent of plasma adiponectin levels in both female and male mice. Overexpression of adiponectin did not alter the number of macrophages in the lesion or the amount of collagen deposition ( Figure 5D and 5E). Positive staining for collagen was localized to regions surrounding the necrotic core in plaques from both Ldlr Ϫ/Ϫ and Ldlr/Adn Tg mice. Visual analysis of the staining using a score from 0 to 10, with 10 being the highest intensity, revealed no significant differences within the genotypes (scores of 5.5Ϯ4.9 for Ldlr Ϫ/Ϫ mice and 3.4Ϯ2.8 for Ldlr/Adn Tg mice). CD68positive macrophages were localized throughout the plaques, with the greatest abundance near the subendothelial space ( Figure 5E ), but the content and distribution were unaffected by the genotype (scores of 5.3Ϯ3.2 for Ldlr Ϫ/Ϫ and 4.7Ϯ3.8 for Ldlr/Adn Tg mice). Our data demonstrate that genetic elevation of adiponectin has no effect on the formation of lesions despite some beneficial effects on lipid clearance and plasma lipids in the Ldlr Ϫ/Ϫ atherosclerosis model.
Discussion
The role of adiponectin in cardiovascular disease has been met with considerable interest and examined in a large number of epidemiological studies. A picture has emerged suggesting that high adiponectin levels are predictive of a lower incidence of cardiovascular disease in the general population. However, when examined at later stages of cardiovascular disease, high adiponectin levels are indicative of an increased rate of mortality from cardiovascular disease in humans. 31 This may reflect a compensatory upregulation of a beneficial factor in light of a generally disadvantageous cardiovascular environment, through a mechanism that is far from understood.
Studies in preclinical models also suggest that adiponectin is more than an innocent bystander and convenient marker for cardiovascular integrity. An association between low adiponectin and increased vascular thickening has been suggested on the basis of a mouse cuff-injury model. 32 In vitro experiments attributed a potent antiinflammatory role to the globular form of adiponectin, and Okamoto et al demonstrated that globular adiponectin suppressed lipopolysaccharide-induced cytokine release in macrophages and suppressed T-lymphocyte accumulation in atherogenesis in Apoe Ϫ/Ϫ mice. 33 Our study is the first to address the function of the full-length form of adiponectin secreted in its native conformation. We are also the first to address the role of adiponectin in the Ldlr Ϫ/Ϫ mouse model, which develops atherosclerosis only after supplementation of high levels of dietary cholesterol. 16 We used diets that cause substantial hypercholesterolemia but differentially affect the degree of adiposity, insulin resistance, and inflammation. Surprisingly, while observing the expected differential susceptibility to the diets with respect to insulin sensitivity, we failed to detect an effect on atherosclerosis in both genetic adiponectin gain-and loss-offunction mice. Our data differ from those of previous reports derived from the Apoe Ϫ/Ϫ model, which may be best explained by differences in the experimental paradigm, the form of adiponectin supplied, and the diets used.
As described previously, 5 introduction of the Adn Tg caused reduction of plasma lipids in our studies; however, mice on an Ldlr Ϫ/Ϫ background remained extremely hypercholesterolemic. We conclude that adiponectin plays an important role in the regulation of plasma lipids; however, the severity of hyperlipidemia in Ldlr Ϫ/Ϫ mice may prevent conclusions about the role of adiponectin under physiological conditions. Similarly, elevation of adiponectin levels by pharmacological means did not affect atherosclerosis in the Ldlr Ϫ/Ϫ model. In fact, COOH treatment caused a small but significant increase in lesion area in the BCA in males. PPAR␥ is highly expressed in macrophage-derived foam cells and has been implicated in the development of atherosclerosis. Most but not all preclinical studies described a reduction of atherosclerosis coinciding with an improvement of overall metabolic parameters. 21, 22, 34 Another study suggested that pioglitazone increased macrophage apoptosis and plaque necrosis in nondiabetic Ldlr Ϫ/Ϫ mice. 15 We chose to study lean, insulinsensitive mice using a nonobesogenic diet in the hope of dissociating direct actions of adiponectin on the vascular wall from secondary effects related to a metabolic improvement. Notably, we did not observe any signs of reduction of atherosclerosis on treatment with COOH, despite a large number of samples.
Our findings underline potential limitations of the LDL receptor mouse model in reproducing associations that have been established in humans. Mice are generally resistant to plaque rupture and myocardial infarction. In our studies, genetic or pharmacological manipulation of adiponectin levels in traditional rodent models did not correlate with atherosclerosis, suggesting that adiponectin is not involved in advanced plaque progression. 
